Bouter Jordan, Reznik Yves, Thariat Juliette
Radiotherapy Department, Centre François Baclesse, Avenue du Général Harris, 14000 Caen, France.
Department of Endocrinology, University Hospital of Caen, Avenue de la Côte de Nacre, 14033 Caen, France.
Cancers (Basel). 2023 Jul 27;15(15):3820. doi: 10.3390/cancers15153820.
Knowledge about the precise effects of radiotherapy on hypothalamo-pituitary functions is limited. Reduction of side effects is a major goal of advanced radiotherapy modalities. We assessed strategies for monitoring and replacement of hormone deficiencies in irradiated patients.
A search strategy was systematically conducted on PubMed. Additional articles were retrieved to describe endocrine mechanisms.
45 studies were evaluated from 2000 to 2022. They were predominantly retrospective and highly heterogeneous concerning patient numbers, tumor types, radiotherapy technique and follow-up. Endocrine deficiencies occurred in about 40% of patients within a median follow-up of 5.6 years without a clear difference between radiotherapy modalities. Somatotropic and thyrotropic axes were, respectively, the most and least radiosensitive.
Current pituitary gland dose constraints may underestimate radiation-induced endocrine deficiencies, thus impairing quality of life. Little difference might be expected between radiation techniques for PG tumors. For non-PG tumors, dose constraints should be applied more systematically.
关于放射治疗对下丘脑 - 垂体功能的确切影响的知识有限。减少副作用是先进放射治疗模式的主要目标。我们评估了监测和替代受照射患者激素缺乏的策略。
在PubMed上系统地进行了检索策略。检索了其他文章以描述内分泌机制。
对2000年至2022年的45项研究进行了评估。这些研究主要是回顾性的,在患者数量、肿瘤类型、放射治疗技术和随访方面高度异质。在中位随访5.6年期间,约40%的患者出现内分泌缺乏,不同放射治疗模式之间无明显差异。生长激素轴和促甲状腺激素轴分别是最和最不放射敏感的。
当前的垂体剂量限制可能低估了辐射诱导的内分泌缺乏,从而损害生活质量。对于垂体瘤,放射技术之间可能预期差异不大。对于非垂体瘤,剂量限制应更系统地应用。